Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES FISCAL YEAR 1992 RESULTS

 CAMBRIDGE, Mass., Nov. 19 ~PRNewswire~ -- PerSeptive Biosystems, Inc. (NASDAQ-NMS: PBIO) today reported results for the year ended Sept. 30, 1992. Revenues for the year were $5,008,000 compared with revenues of $887,000 for the fiscal year ended Sept. 30, 1991. The company recorded a net loss of $3,282,000 or $0.56 per share, in 1992, as compared with a net loss of $3,862,000, or $0.76 per share, in 1991. Primarily as a result of the company's initial public offering in May of this year weighted average shares outstanding increased from 5,802,561 in 1991 to 7,251,196 in 1992.
 Noubar B. Afeyan, Ph.D., president and chief executive officer of the company, commented: "Fiscal 1992 was a remarkable year for the company. We increased revenues more than five-fold. This increase was due to a more than doubling in the sales of POROS(R) media for Perfusion Chromatography(R) and the introduction of the BioCAD(tm) Workstation. We believe that BioCAD represents one of the most powerful and most successful instruments ever developed for the biotechnology industry. In purchasing more than 50 BioCAD Workstations in its first year on the market, our customers have demonstrated growing acceptance of Perfusion Chromatography technology."
 "During the past fiscal year, we also successfully completed our initial public offering of common stock," Dr. Afeyan added. "We are grateful for the continuing confidence that our shareholders have demonstrated in the company, and we are working hard to justify that support."
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 ----
 NOTE TO EDITORS: Perfusion Chromatography and POROS(R) are registered trademarks and BioCAD, ImmunoDetection, and Rational Surface Design are trademarks of the company.
 PERSEPTIVE BIOSYSTEMS, INC.
 Selected Financial Information
 Three Months Ended Fiscal Year Ended
 Sept. 30, Sept. 30,
 1992 1991 1992 1991
 Revenue $2,051,000 $398,000 $5,008,000 $887,000
 Costs of goods
 sold 794,000 156,000 1,923,000 361,000
 Gross profit 1,257,000 242,000 3,085,000 526,000
 Operating expenses 2,002,000 1,236,000 6,619,000 4,304,000
 Loss from operations(745,000) (994,000) (3,534,000) (3,778,000)
 Other income
 (expense) 193,000 5,000 252,000 (84,000)
 Net loss $(552,000) $(989,000) $(3,282,000)$(3,862,000)
 Net loss per
 share (6 cents) (19 cents) (56 cents) (76 cents)
 Weighted average
 shares 8,844,378 6,270,545 7,251,196 5,802,561
 Selected Balance Sheet Data
 September 30,
 1992 1991
 Cash and investments $17,174,000 $3,443,000
 Total assets $22,209,000 $5,042,000
 Total indebtedness $2,912,000 $1,099,000
 Total stockholders
 equity $19,297,000 $3,943,000
 -0- 11~19~92
 ~CONTACT: Robert A. Fein, vice president and chief financial officer of PerSeptive Biosystems, 617-621-1787; or Pam Haslam, senior vice president of Feinstein Partners, 617-577-8110, for PerSeptive Biosystems~
 (PBIO)


CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU: ERN

CH -- NE001 -- 2677 11~19~92 08:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1992
Words:567
Previous Article:ROCKWELL INTERNATIONAL'S BOOT CAMPS PROVIDE DRILLFIELD FOR QUALITY
Next Article:COMPAQ ESTABLISHES WORLD-CLASS TRAINING CENTER IN CHINA
Topics:


Related Articles
ROBERT A. FEIN PROMOTED TO SENIOR VICE PRESIDENT, FINANCE FOR PERSEPTIVE BIOSYSTEMS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES SECOND QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES FISCAL 1993 RESULTS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES FIRST QUARTER FINANCIAL RESULTS; $0.05 EARNINGS PER SHARE BEFORE PTC-I BUYOUT
PERSEPTIVE BIOSYSTEMS AGREES TO ACQUIRE PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS TO COMBINE ITS DRUG DISCOVERY GROUP WITH MYCO PHARMACEUTICALS TO FORM CHEMGENICS PHARMACEUTICALS
PERSEPTIVE BIOSYSTEMS REPORTS RESULTS FOR SECOND FISCAL QUARTER OF 1996
PERSEPTIVE BIOSYSTEMS, INC. COMPLETES TRANSACTION WITH CHEMGENICS PHARMACEUTICALS
PerSeptive Biosystems Reports Results for Third Fiscal Quarter of 1996
Perseptive Biosystems Realizes $12.9 Million From Selling Portion of Stock in Millennium Pharmaceuticals

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters